Acknowledgement
This research was supported by the Seoul National University Bundang Hospital research fund (No. 06-2019-0050) and the National Research Foundation of Korea Grant funded by the Korean Government (2021K1A4A7A02097757).
References
- Song J, Park DW, Cha JH, Seok H, Kim JY, Park J, et al. Clinical course and risk factors of fatal adverse outcomes in COVID-19 patients in Korea: a nationwide retrospective cohort study. Sci Rep 2021;11:10066.
- World Health Organization. Coronavirus disease 2019 (COVID-19) pandemic [Internet]. Geneva: WHO; 2023 [cited 2023 Feb 18]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
- National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines [Internet]. Bethesda: NIH; 2023 [cited 2023 Feb 18]. Available from: https://www.covid19treatmentguidelines.nih.gov/.
- Buszko M, Park JH, Verthelyi D, Sen R, Young HA, Rosenberg AS. The dynamic changes in cytokine responses in COVID-19: a snapshot of the current state of knowledge. Nat Immunol 2020;21:1146-51. https://doi.org/10.1038/s41590-020-0779-1
- World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance, 25 January 2020 [Internet]. Geneva: WHO; 2020 [cited 2023 Feb 18]. Available from: https://apps.who.int/iris/handle/10665/330854.
- Zang X, Xiong L, Zhu J, Zhao F, Wang S, Zeng W, et al. The value of early positive nucleic acid test and negative conversion time of SARS-CoV-2 RNA in the clinical outcome of COVID-19 patients. Front Med (Lausanne) 2022;9:826900.
- Milani L, Cigliano F, Catalano A, Macciotta A, Viola M, Caramello V, et al. Characteristics of patients affecting the duration of positivity at SARS-CoV-2: a cohort analysis of the first wave of epidemic in Italy. Epidemiol Prev 2021;45:533-42.
- Huai Luo C, Paul Morris C, Sachithanandham J, Amadi A, Gaston DC, Li M, et al. Infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant is associated with higher recovery of infectious virus compared to the alpha variant in both unvaccinated and vaccinated individuals. Clin Infect Dis 2022;75:e715-25. https://doi.org/10.1093/cid/ciab986
- Korea Disease Control and Prevention Agency. Outbreak report of COVID-19 during designation of class 1 infectious disease in the Republic of Korea (January 20, 2020 and April 24, 2022) [Internet]. Cheongju: KDCA; 2022 [cited 2023 Feb 18]. Available from: https://www.kdca.go.kr/board/board.es?mid=a30501000000&bid=0031&list_no=719926&act=view#.
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83. https://doi.org/10.1016/0021-9681(87)90171-8
- Glasheen WP, Cordier T, Gumpina R, Haugh G, Davis J, Renda A. Charlson comorbidity index: ICD-9 update and ICD-10 translation. Am Health Drug Benefits 2019;12:188-97.
- Hodcroft E. SARS-CoV-2 mutations and variants of interest [Internet]. CoVariants; 2023 [cited 2023 Feb 18]. Available from: https://covariants.org.
- Shiehzadegan S, Alaghemand N, Fox M, Venketaraman V. Analysis of the Delta variant B.1.617.2 COVID-19. Clin Pract 2021;11:778-84. https://doi.org/10.3390/clinpract11040093
- Starr TN, Greaney AJ, Dingens AS, Bloom JD. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep Med 2021;2:100255.
- Shi R, Shan C, Duan X, Chen Z, Liu P, Song J, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 2020;584:120-4. https://doi.org/10.1038/s41586-020-2381-y
- McKeigue PM, McAllister DA, Hutchinson SJ, Robertson C, Stockton D, Colhoun HM. Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study. Lancet Respir Med 2022;10:566-72. https://doi.org/10.1016/S2213-2600(22)00045-5
- WHO Solidarity Trial Consortium; Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, et al. Repurposed antiviral drugs for COVID-19: interim WHO solidarity trial results. N Engl J Med 2021;384:497-511. https://doi.org/10.1056/NEJMoa2023184
- Winstead RJ, Christensen J, Sterling S, Morales M, Kumar D, Bryson A, et al. Effect of remdesivir on COVID-19 PCR positivity and cycle threshold in kidney transplant recipients. Transplantology 2021;2:291-3. https://doi.org/10.3390/transplantology2030028
- Jefferson T, Spencer EA, Brassey J, Heneghan C. Viral cultures for coronavirus disease 2019 infectivity assessment: a systematic review. Clin Infect Dis 2021;73:e3884-99. https://doi.org/10.1093/cid/ciaa1764
- Shenoy S. SARS-CoV-2 (COVID-19), viral load and clinical outcomes; lessons learned one year into the pandemic: a systematic review. World J Crit Care Med 2021;10:132-50. https://doi.org/10.5492/wjccm.v10.i4.132
- Ynga-Durand M, MaaB H, Milosevic M, Krstanovic F, Pribanic Matesic M, Jonjic S, et al. SARS-CoV-2 viral load in the pulmonary compartment of critically ill COVID-19 patients correlates with viral serum load and fatal outcomes. Viruses 2022;14:1292.
- Salto-Alejandre S, Berastegui-Cabrera J, Camacho-Martinez P, Infante-Dominguez C, Carretero-Ledesma M, Crespo-Rivas JC, et al. SARS-CoV-2 viral load in nasopharyngeal swabs is not an independent predictor of unfavorable outcome. Sci Rep 2021;11:12931.
- Mizrahi B, Bivas-Benita M, Kalkstein N, Akiva P, Yanover C, Yehezkelli Y, et al. Results of an early second PCR test performed on SARS-CoV-2 positive patients may support risk assessment for severe COVID-19. Sci Rep 2021;11:20463.